Creator: Dr. Reeja Tharu
Keywords: Prostate Cancer, Cancer of Prostate, References for Prostate cancer prostate cancer reference

References for Prostate Cancer

Author: Dr. Reeja Tharu

Editor: The Medindia Medical Review Team

Technically Checked by: Lingaraj

Published on Mar 03, 2016
Last Updated on Feb 21, 2022

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

APA

Dr. Reeja Tharu. (2022, February 21). Prostate Cancer | Cancer of Prostate - References. Medindia. Retrieved on May 28, 2022 from https://www.medindia.net/patientinfo/prostate-cancer-references.htm.
MLA

Dr. Reeja Tharu. "Prostate Cancer | Cancer of Prostate - References". Medindia. May 28, 2022. <https://www.medindia.net/patientinfo/prostate-cancer-references.htm>.
Chicago
Dr. Reeja Tharu. "Prostate Cancer | Cancer of Prostate - References". Medindia. https://www.medindia.net/patientinfo/prostate-cancer-references.htm. (accessed May 28, 2022).
Harvard
Dr. Reeja Tharu. 2021. Prostate Cancer | Cancer of Prostate - References. Medindia, viewed May 28, 2022, https://www.medindia.net/patientinfo/prostate-cancer-references.htm.

<< Latest Publications and Research

Do you wish to consult an Andrologist for your problem? Ask your question

Dr. Joe Kaushik

MBBS, MS, OBG,FAMH
15 years experience

Teleconsult Now View Profile

View All

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.

@Guest

what are the chances of prostate cancer after the age of 69yrs.

Reply | Forward

prema

Abiraterone in prostate cancer

The big news in oncology has been Johnson and Johnson purchasing Cougar Biotechnology for $1 billion. They have just bought promising prostate cancer compound, abiraterone.

So look out for this oral drug.

Dr.Shroff
The data hasn't even been announced at ASCO yet, that's this weekend coming, so one can only speculate that suitors got a sneak peek of the data under an NDA. A billion dollars certainly gets attention and raises the ante for future small oncology biotech deals.